Virginia C. Broudy, MD
University of Washington School of Medicine, Seattle, WA
This case was reviewed and updated in August 2013 by Dr. Eric Kraut and members of the Teaching Cases Subcommittee.
Copyright of the American Society of Hematology, 2006. ISSN: 1931-6860.
Di Nisio M. The hematocrit and platelet target in polycythemia vera. Br J Haematol. 2006;136:249-259.
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;360:22-23.
Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214-4222.
Spivak J. Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations. Ann Intern Med. 2010;152:300-306.
Tefferi A. Polycythemia and essential thrombocytosis. Am J Hemat. 2013;88:508-516.
Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91:174-179.
Have a question or comment about the ASH Teaching Cases? Please e-mail email@example.com.